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Abstract
Background: RecQ helicases play an essential role in the maintenance of genome stability. In humans, loss of
RecQ helicase function is linked with predisposition to cancer and/or premature ageing. Current data show that
the specific depletion of the human RECQ1 helicase leads to mitotic catastrophe in cancer cells and inhibition of
tumor growth in mice.
Results: Here, we show that RECQ1 is highly expressed in various types of solid tumors. However, only in the case
of brain gliomas, the high expression of RECQ1 in glioblastoma tissues is paralleled by a lower expression in the
control samples due to the poor expression of RECQ1 in non-dividing tissues. This conclusion is validated by
immunohistochemical analysis of a tissue microarray containing 63 primary glioblastomas and 19 perilesional tissue
samples, as control. We also show that acute depletion of RECQ1 by RNAi results in a significant reduction of
cellular proliferation, perturbation of S-phase progression, and spontaneous g-H2AX foci formation in T98G and U-
87 glioblastoma cells. Moreover, RECQ1 depleted T98G and U-87 cells are hypersensitive to HU or temozolomide
treatment.
Conclusions: Collectively, these results indicate that RECQ1 has a unique and important role in the maintenance
of genome integrity. Our results also suggest that RECQ1 might represent a new suitable target for anti cancer
therapies aimed to arrest cell proliferation in brain gliomas.
Background
RecQ helicases are a ubiquitous family of DNA unwind-
ing enzymes involved in the maintenance of chromo-
some stability. Five members of the RecQ family have
been found in human cells: BLM, RECQ1 (also known
as RECQL or RECQL1), RECQ4, RECQ5, and WRN
[1-3]. Mutations in the genes of three human RecQ
family members are linked to defined genetic disorders
associated with genomic instability, cancer predisposi-
tion and features of premature ageing; namely, Bloom’s
syndrome (BLM gene mutations), Werner’ss y n d r o m e
(WRN gene mutations), and Rothmund-Thomson syn-
drome (RTS), RAPADILINO and Baller-Gerold syn-
d r o m e( a l lc a u s e db ym u t a t i o no fRECQ4) [4-8].
Mutations in the RECQ1 and RECQ5 genes may be
responsible for additional cancer predisposition disor-
ders, but this remains to be proven. In this regard, inter-
esting candidates are patients with a phenotype similar
to that of RTS individuals who do not carry any muta-
tions in the RECQ4 gene. Moreover, recent studies have
linked a single nucleotide polymorphism present in the
RECQ1 gene to a reduced survival in pancreatic cancer
patients [9,10].
Biochemical studies have demonstrated that RecQ
helicases unwind DNA with a 3’ to 5’ polarity and,
although with some differences, are capable of unwind-
ing a variety of DNA structures other than standard B-
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to unwind various DNA structures, several cellular func-
tions have been attributed to RecQ proteins, including
roles in stabilization and repair of damaged DNA repli-
cation forks, telomere maintenance, homologous recom-
bination, and DNA damage checkpoint signaling
[13-15].
Previous studies demonstrated that BLM is highly
expressed in tumor cells of both lymphoid and epithelial
origin and that this reflects the greater fraction of prolif-
erating cells that are present in tumors relative to the
normal tissues of the same origin [16]. Similarly, WRN
was also recently suggested to be involved in the promo-
tion of tumor cell growth [17]. A cancer specific role of
RECQ1 is supported by recent reports showing that
RECQ1 silencing in cancer cells resulted in mitotic cata-
strophe and local and systemic administration of
RecQL1-siRNA prevented tumor growth in murine
models [18-20].
Here, we characterized the expression of RECQ1 in
normal and neoplastic tissues of different origins by
immunohistochemical and western blot analysis. Our
results show that RECQ1 is highly expressed in tumors.
In particular, its expression level increases dramatically
in human brain glioblastoma relative to control brain
tissues. We also show that RECQ1 depletion affects pro-
liferation of glioblastoma cells and causes an increased
level of DNA damages supporting the notion that
R E C Q 1p l a y sau n i q u er o l ei nt h em a i n t e n a n c eo fg e n -
ome stability. Moreover, RECQ1 depleted cells are
hypersensitive to hydroxyurea (HU) or temozolomide
treatment, the latter of which is an anticancer agent
widely used for the treatment of human brain tumors.
In this regard, glioblastoma is the most common and
aggressive histotype of brain tumor with a very poor
prognosis [21,22]. One of the reasons why glioblastomas
are so difficult to combat is that they are associated
with a diffuse invasion of distant tissues by a multitude
of migrating gliomas cells characterized by a decreased
level of apoptosis and an increased resistance to cyto-
toxic insults due to the activation of specific signalling
pathways [21]. Given that these pathways are not all
activated at the same time in all gliomas, the develop-
ment of specific inhibitors to combat the migratory
glioma cells would only be possible if molecular profil-
ing of the tumors of the individual patients is per-
formed. Recent studies reported that the median and 2-
year survival rate of patient with glioblastoma was how-
ever significantly improved by the addition of concomi-
tant and adjuvant temozolomide to standard
postoperative radiotherapy [22]. Temozolomide has the
ability to overcome the intrinsic resistance of cancer
cells to apoptosis since it works both as a proautoptic
and proautophagic cytotoxic drug, thus inducing cell
death both by apoptosis and autophagy [23,24]. More-
over, patients characterized by a methylated form of the
promoter for the O-6-methylguanine-DNA-methyltrans-
ferase (MGMT) gene are more likely to benefit from
temozolomide treatment [22]. Even if considerable
advancements in glioblastoma treatment have been
made during the recent years, new therapeutic protocols
are highly needed.
Methods
Antibodies
The custom rabbit polyclonal anti-RECQ1 antibody
against the C-terminal region of RECQ1 (RQ-CT) was
raised against a 16 amino acid peptide corresponding to
residues 634-649 of RECQ1 (C-SGSKNTGAKKR-
KIDDA) with an N-terminal cysteine conjugated to the
keyhole limpet hemocyanin (KLH) carrier protein
(Sigma Genosys). The rabbit polyclonal anti-RECQ1
antibody against the full-length RECQ1 (RQ-FL) was
made by injecting the rabbits with full-length recombi-
nant RECQ1 expressed in insect cells [25]. Antibodies
against RECQ1 (sc-25547), RAD51 (sc-8349) were from
Santa Cruz Biotechnology. Anti-g-H2AX pSer139 (05-
636), anti-BrdU-FITC (347583) and anti-a-Tubulin
(T6074) were obtained from Upstate, BD Bioscience and
Sigma, respectively. Antibody against Ki-67 (pre-diluted
MIB-1, clone 30-9) was from Ventana Medical System.
The anti-MGMT (ab39253) antibody was obtained from
Abcam. The Glial Fibrillary Acidic Protein (GFAP) anti-
body (pre-diluted, clone EP672Y) was from Cell Marque.
The secondary Alexa 488-, Alexa 594-conjugated antibo-
dies and Toto-3 iodide were from Invitrogen Molecular
Probes.
Cells lines
Human glioblastoma (T98G (ATCC, CRL-1690) and U-
87 (ATCC, HTB-14)) and normal human fibroblast
(IMR-90) (ATCC, CCL-186)) cell lines were maintained
in Dulbecco’s modified Eagle’s Medium (DMEM) and
MEM media supplemented with Glutamax (Life Tecnol-
ogies, Inc.) and 10% (v/v) fetal bovine serum (FBS; Life
Technologies, Inc.), respectively.
Tissues
The tumoral and perilesional brain tissues samples were
provided by the Neurosurgery Unit of the “Azienda
Ospedaliero-Universitaria” of Udine, while the tumoral
and perilesional tissues samples of colon, lung, and thyr-
oid plus the normal heart tissue were provided by the
ACADEM Department of the Cattinara hospital of
Trieste, Italy. The tissues were obtained by surgical
resection and they were fixed in formalin and paraffin
embedded. In the case of the brain tumors, a portion of
the biopsy tissue was kept at -80°C for the subsequent
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firmed in each case by histopathological analysis. Sec-
tions of 4 μm thickness were prepared and mounted on
SuperFrost
® Plus microscope slides. After overnight dry-
ing at 37°C, the slides were processed for immunostain-
ing. The percentage of nuclei showing positive staining
with the antibodies was calculated counting three high
power fields (HPF) and making the average. The immu-
nostaining with the RQ-FL and RQ-CT antibodies was
comparable.
Immunohistochemistry (IHC)
IHC staining was performed on 4 μm-thick tissue sec-
tions that were cut with the microtome from formalin-
fixed, paraffin-embedded samples representative of the
following tumors: glioblastoma, colon tumors, thyroid
tumor and lung tumor. The sections were deposited on
SuperFrost
® Plus slides and incubated at least for 12
hours at 37°C. The immunostaining procedures were
performed automatically using the Benchmark device
(Ventana Medical System, Tucson, AZ, USA) and
manually, using heat-induced epitope retrieval method.
The detection of RECQ1 was performed using the poly-
clonal antibody produced in rabbit which recognizes the
full protein sequence (RQ-FL), or the antibody directed
against the last 16 residues at the C-terminus (RQ-CT),
both at 1:150 dilution; the immunodetection of Ki-67
was performed using the Ventana pre-diluted MIB-1
antibody and the antibody anti-MGMT was used a
1:150 dilution. All these antibodies were detected using
chromogen diaminobenzidine (DAB). For the manual
detection, the incubations were performed in a humidi-
fied chamber. Briefly, tissue sections, were deparaffi-
nized, immersed in xylene for 30 min, and then
hydrated in a decreasing alcohol series. Endogenous per-
oxidase activity was blocked by incubating the tissue
sections in 0.3% H2O2 for 20 min. For RECQ1 detection,
the sections were subject to heat-induced epitope retrie-
val, immersing the slides in boiling 10 mM citrate buf-
fer, pH 6.0 for 20 min; for Ki-67 staining, we performed
heat antigen retrival with 100 mM Tris-Borate, 1 mM
EDTA pH 8.0 solution. The sections were incubated for
20 minutes with blocking serum (Vectastain Universal
Elite ABC kit, Vector Laboratories, Burlingame, CA,
USA) and for 60 minutes with the primary antibody
directed against RECQ1, 1:150 diluted. The sections not
incubated with the primary antibody were used as nega-
tive controls. The slides were washed for some times
with PBS and 0.1% of Triton X-100, and incubated for
30 minutes with the biotinylated secondary antibody
and with Vectastain ABC system for 30 minutes (Vec-
tastain Universal Elite ABC kit, Vector Laboratories,
Burlingame, CA, USA); the detection was made using a
solution containing DAB and H2O2 (DAB substrate kit,
Vector Laboratories, Burlingame, CA, USA). The sec-
tions were counterstained with Mayer hematoxylin. Pre-
adsorption of the antibody, using a molar excess of the
specific immunizing peptide (1:5 at 37°C for 30 min)
was performed to verify the antibody specificity.
Glioblastoma tissue microarray construction
Multiform glioblastoma (GBM) tissue samples were col-
lected from the archives of the Pathology Department of
the Cattinara Hospital of Trieste, Italy. A tissue microar-
ray (TMA) was constructed collecting 63 lesional and 19
perilesional tissues; specifically, the array had a total of
82 cores. The tissue cores were related to 63 patients
whose diagnosis was primary glioblastoma. These
patients were randomly selected from the clinical records
of the Cattinara Hospital from 01/01/2003 to 31/12/
2009. The selection criteria were a primary diagnosis of
glioblastoma, no relapses or metastases were inserted in
the TMA. Among the 63 patients, 29 were males with a
median age of 65 years (range 42-84) and 33 were
females with a median age of 62 years (range 42-81).
Areas showing the histopathologic features of GBM
and perilesional tissue were selected on archival hema-
t o x y l i na n de o s i n( H & E )s l i d e s ,a n dm a r k e df o rT M A
construction. Briefly, after the tissue cylinders of 1.5
mm in diameter were taken from the selected regions of
the donor paraffin block, they were punched into a reci-
pient paraffin block using a tissue-arraying instrument
(Galileo TMA CK3500, from by Integrated Systems
Engineering, Milano, Italy). Sections of 4 μm thick were
prepared and mounted on microscope slides. After over-
n i g h td r y i n ga t3 7 ° C ,t h es l i d e sw e r ep r o c e s s e df o r
immunostaining. An H&E stained section was also
made to confirm the presence of the original areas
selected from each tumor. The TMA sections were eval-
uated by two pathologists to validate the diagnostic
morphology of each array spot.
The TMA sections were stained with RECQ1 (diluted
1:150, RQ-CT), Ki-67, MGMT and the Glial Fibrillary
Acidic Protein (GFAP) antibodies for IHC analysis. The
antibodies were detected using chromogen diaminoben-
zidine (DAB). The procedure for IHC analysis of the
TMA was the same described in the paragraph above
with the exception that a buffer containing 100 mM
Tris-Borate, 1 mM EDTA pH 8.0 was used for the anti-
gen retrieval in the case of Ki-67 and GFAP. IHC
against GFAP, which is a specific marker of the astro-
cytes, allowed discriminating the astrocytes from oligo-
dendrocytes and support neurons (negative to GFAP
staining). During the cell counting for RECQ1, only the
astrocytes’ positivity was considered. The percentage of
nuclei showing positive staining with the antibodies was
calculated counting three high power fields (HPF) and
making the average.
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For the qualitative detection of MGMT gene promoter
methylation status, DNA was extracted from FFPE tis-
sues of each tumor samples. The tissues’ specimens
were deparaffinized, DNA was extracted and chemically
modified by bisulfite treatment for subsequent methyla-
tion specific PCR analysis according to a previously
described protocol [26]. For sequence analysis of typical
somatic mutations in the IDH1 and IDH2 genes, DNA
from tissues’ specimens was extracted following the
same protocol used for DNA methylation analysis, while
for the T98G and U87 cell lines DNA was extracted
according to the manufacture’s instructions using the
Wizard Genomic DNA purification Kit (Promega). PCR
analysis was performed as already reported [27]. Ampli-
cons were purified by a PCR purification kit (Qiagen)
and sequenced by Sanger’s method.
Statistical Analysis
The Wilcoxon test (non parametrical) for matched-sam-
ples was used to evaluate differences in IHC analyses
between tumor tissues and corresponding normal peri-
lesional tissues. IHC results considered in this analysis
were: the number of positive cells for RECQ1, the inten-
sity of the signal and the number of positive cells for
Ki-67. Spearman’s correlation test was applied to assess
the relationship between intensity score of RECQ1 and
the number of positive cells in lesional tissues. Kruskal-
W a l l i st e s tw a sa p p l i e dt oi n v estigate differences in the
percentage of positive cells for Ki-67 and RECQ1 among
groups defined by the gender of the patients and the
intensity score of RECQ1. The above statistical tests
were also applied to investigate if there was any correla-
tion between the percentage of RECQ1 positive cells
and the methylation status of the MGMT gene or the
expression level of the MGMT protein in primary glio-
blastomas showing an intensity score of 3+ for RECQ1.
Two-sided probability values of less than 0.05 were con-
sidered to indicate statistical significance. Statistical ana-
lyses were performed using Stata SE 9.2 software (Stata
Corp College Station, TX, USA).
Cells and cell cycle analysis
Glioblastoma (T98G and U-87) and normal human
fibroblast (IMR-90) cell lines were maintained in
DMEM and MEM media supplemented with Glutamax
(Life Tecnologies, Inc.) and 10% (v/v) fetal bovine serum
(FBS; Life Technologies, Inc.), respectively. BrdU incor-
poration experiments were performed on transiently
siRNA transfected cells 72 h post-transfection. Cells
were pulsed for 1 h with BrdU (Sigma, final concentra-
tion 10 μM), and BrdU-positive cells were detected by
using a mouse anti-BrdU-FITC primary antibody fol-
lowed by an anti-mouse Alexa 488-conjugated
secondary antibody. Cells were collected and analyzed
by flow cytometry on a FACSCalibur (Becton Dickinson)
to simultaneously determine the cell-cycle profile (DNA
content) by incorporation of propidium iodide (Sigma)
and the S-phase cell population by incorporation of
BrdU. Cell cycle profile distributions were determined
with the CellQuestPro and Modfit LT 3.0 software.
Immunoblotting
Brain tissues extracts were prepared in buffer TNEN (50
mM Tris pH 7.5, 150 mM NaCl, 2 mM EDTA, 0.2% tri-
ton X-100 and 0.3% NP-40) following a previously
described procedure [28]. T98G, U-87, and IMR-90
whole cell extracts were prepared in HNNG buffer (15
mM Hepes pH 7.5, 250 mM NaCl, 1% (v/v) NP-40, 10%
(v/v) glycerol, 1 mM PMSF) supplemented with 0.2 mM
sodium orthovandate (Sigma), 10 mM sodium glycerol-
2-phosphate (Sigma), 25 mM NaF (Sigma) and protease
inhibitors cocktail tablet (Roche). Immunoblots were
carried out with 2 to 10 μg of whole-cell lysates. Pro-
teins were separated on 12% SDS-PAGE gel and
detected by immunoblotting using the SuperSignal West
Femto Maximum Sensitivity Substrate (Pierce).
RNA interference
Cells were transiently transfected with a commercial mix
of 4 siRNAs against RECQ1 (NM_032941: Dharmacon-
SMARTpool; target sequences: GAGCUUAUGUUAC
CAGUUA, CUACGGCUUUGGAGAUAUA, GAUUAU
AAGGCACUUGGUA, GGGCAAGCAAUGAAUAUGA)
for 72 hours at 100 nM final concentration using the
Hyperfect transfection system (QIAGEN) and following
the manufacturer’s instructions. The specificity of this
siRNA mix was already confirmed in our previous study
[29]. RNAi control experiments were performed using a
siRNA against Luciferase (Dharmacon). Alternatively, an
efficient reduction of the expression level of RECQ1 in
the T98G cells was also obtained by transfection with a
pcDNASup plasmid (hybrid plasmid obtained by combi-
nation of pcDNA3) (Invitrogen, life technologies) and
pSUPER (OligoEngine) encoding a shRNA (short hairpin
RNA) against RECQ1 mRNA (target sequence (target):
5’-GAGCUUAUGUUACCAGUUA-3’). The T98G cell
clones downregulated for RECQ1 were obtained by
selection with Geneticin G418 antibiotic (0.5 mg/L)
(GIBCO BRL).
Clonogenic assays
Colony forming assays were conducted in vitro as
already described [30]. Briefly, the assays were per-
formed in six-well plates, with clones produced either
by transfection with a luciferase-siRNA duplex as con-
trol or with a RECQ1-siRNA. Additionally, clonogenic
assays were carried out on stable clones produced by
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or clones obtained from T98G cells transfected with the
pcDNASup containing RECQ1-shRNA. Cells were
seeded at different dilutions (100, 200, 400, 800, 1600
and 3200 cells per well) in six-well plates, and the colo-
nies formed after at least one week of growth were
counted using VersaDoc 4000 imaging system (BioRad).
Proliferative capacity of control cells and of the RECQ1-
depleted cells was evaluated by their plating efficiency
(PE) and expressed as colony forming capacity. The PE
was calculated as the average ratio of the number of
formed colonies versus the number of cells seeded,
expressed as percentage. Cell survival assays were per-
formed by plating transfected cells before treatment
with hydroxyurea (HU: Sigma) or temozolomide (TMZ:
Sigma). Cells were treated overnight with different doses
of HU (0.2, 2, 10 and 20 mM) or TMZ (5, 50, 250 and
500 μM). Surviving fractions were calculated following a
procedure already published [30].
Immunofluorescence
Briefly, cells were seeded in chamber slides (NALGENE)
after transient downregulation of the level of RECQ1
expression by RNA interference for 24 hours. A second
transfection with the siRNA was repeated immediately
after the cells were seeded in the chamber slides. The
cells were left under these conditions for 72 hours. The
medium was then removed and the chamber slides were
washed, fixed and immunostained by a set of specific
antibodies following a protocol already described [31].
The primary antibodies used in this study were already
described above. The primary antibodies used for the
immunofluorescence analysis are described in the first
“Material and Methods” paragraph. The slides were then
incubated with the secondary Alexa 488 and Alexa 594
fluorophores-conjugated antibodies (Invitrogen, Molecu-
lar Probes). Confocal fluorescence analysis was per-
formed on a Zeiss LSM 510 Meta confocal microscope.
Images were acquired using the LSM software. The cells
containing g-H2AX and RAD51 foci were counted in at
least 100 nuclei.
Results
Expression of RECQ1 in human tumor tissues
Immunohistochemical analysis of perilesional sections of
human colon carcinoma, thyroid cancer, lung cancer,
and brain glioblastoma tissues showed that RECQ1 was
effectively detected in these samples. The RECQ1
expression was confined in the cellular nuclei and more
than 30% of cells in each sample stained positive for
RECQ1 using either an antibody raised against the full-
length protein (RQ-FL) or an antibody specifically
recognizing the C-terminus of RECQ1 (RQ-CT) (Figure
1A). The specificity of the two anti-RECQ1 antibodies
was confirmed by pre-adsorption experiments showing
that after pre-adsorption of the tissue with the recombi-
nant RECQ1 protein only a minimal non-specific stain
could be detected (Figure 1B). The immunohistochem-
ical analysis was then repeated including lesional tissues
from brain glioblastoma, colon carcinoma, lung and
thyroid cancers for comparative analysis (Figure 2). The
results showed that RECQ1 was highly expressed both
in the perilesional sections and in lesional sections of
Figure 1 Comparison of the efficiency of the RQ-FL and RQ-CT
antibodies. A) Representative immunostaining against the RQ-FL
antibody (left) and the RQ-CT antibody (right). All tissues are
perilesional sections from multiform glioblastoma, colon carcinoma,
lung cancer and thyroid cancer. The nuclei positive for the antibody
are in brown and the tissues were counterstained with hematoxylin
(O.M 40X). B) Pre-adsorption experiments using the recombinant
RECQ1 protein on normal colon tissues. Immunostaining against
RQ-FL antibody in colon tissues before (1) and after preadsorption
with the full-length recombinant RECQ1 protein (2). The nuclei
positive for the antibody are in brown and the tissues were
counterstained with hematoxylin (O.M. 40X).
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mas where the expression of RECQ1 was significantly
higher in the tumor samples relative to the perilesional
tissues. In particular, we observed a 4-fold decrease in
the percentage of RECQ1 positive nuclear staining cells
from brain tumor sections versus perilesional tissue
sections.
The higher expression of RECQ1 in brain glioblastoma
was confirmed by Western blot analysis showing that
RECQ1 was at least 10-fold more abundant in the
tumoral tissues compared to the perilesional samples,
where RECQ1 was almost undetectable (Figure 3A). The
same results were also confirmed using autoptic normal
brain tissues, which might represent a more appropriate
control for our experiments since we cannot rule out
the possibility that the perilesional tissues might be par-
tially infiltrated with the tumor. The fact that the perile-
sional and autoptic normal brain tissues showed a lower
number of positive nuclei compared to the control tis-
sues from other types of tumors suggests that RECQ1 is
less expressed in normal non-dividing tissues (Figure
3B). This hypothesis was confirmed by the analysis of a
Figure 2 RECQ1 expression in tumors of different origins. A) Representative micrographies of immunohistochemical analysis on tissues from
different types of tumors. On the left, the perilesional zone and, on the right, the tumoral one. Immunostaining was made using the anti-RECQ1
RQ-FL antibody. The nuclei positive for the protein are in brown and the tissues were counterstained with hematoxylin (O.M 40X). The
histograms on the right represent the percentage of nuclei positive for RECQ1 in perilesional and lesional tissues of the indicated tumors.
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of a non dividing tissue, and did not show any signifi-
cant nuclear staining for RECQ1 (Figure 3C). Collec-
tively, our immunohistochemical analysis of different
tumor samples indicates that RECQ1 is highly expressed
in all types of tumors. However, only in the case of glio-
blastoma this high expression parallels with its lower
expression in the perilesional counterpart due to the
extremely low expression of RECQ1 in non-dividing
tissues.
Tissue microarray analysis
To validate our conclusion that RECQ1 is highly
expressed in glioblastomas, we analyzed the expression
pattern of RECQ1 on a tissue microarray containing a
total of 63 primary glioblastoma and 19 perilesional tis-
sues (Figure 4A,B). In agreement with the previous
results, the percentage of RECQ1 positive cells (95%)
and the intensity of the staining was significantly higher
in tumoral versus perilesional tissues (P = 0.0013 and P
= 0.0009, respectively) (Figure 4C,D). The higher posi-
tivity of primary glioblastoma tissues for RECQ1 corre-
lated with higher intensity of the immunostaining. In
particular, the RECQ1 positive cells of 48 out of 63 glio-
blastoma speciemen present in the TMA showed a
strong nuclear positivity characterized by a staining
nuclear intensity of 3+, while most of the cells positive
for RECQ1 in the perilesional tissues were characterized
by a weaker staining intensity of 2+ (Figure 4D). As
expected, the number of positive cells for Ki-67 differed
significantly between tumors and matched surrounding
normal tissue, with an higher expression of the protein
in the lesional tissues (P = 0.0008) (Figure 4E). GFAP
staining confirmed that in the perilesional area the
majority of cell positive to RECQ1 were astrocytes, even
though some positive staining for RECQ1 was detected
also in the oligodendrocytes and the support neurons
(Additional File 1). However, GFAP staining demon-
strated that only astrocytes presented an intense nuclear
positivity to RECQ1 in tumor tissues.
A detailed IHC analysis of the glioblastoma tissues
present in the TMA indicated that the percentage of
positive cells for Ki-67 and RECQ1 did not differ signifi-
cantly between men and women (P = 0.9 and 0.7,
respectively). Similarly, the age at diagnosis did not cor-
relate with the percentages of positive cells for RECQ1
and Ki-67 (P = 0.4 and P = 1.0), nor with the intensity
of the signal for RECQ1 (P = 0.5). A significant trend
was detected between the percentage of positive cells
and the intensity of the signal for RECQ1 (Spearman’s
rho = 0.5, P = 0.0001) indicating that a high number of
positive cells is associated with a stronger signal. No
correlation was present between the percentage of posi-
tive cells for RECQ1 and Ki-67 (Spearman’s rho = 0.2, P
= 0.2).
Previous studies indicated that the methylation of the
MGMT gene promoter is a strong predictor of the bene-
fit from temolozolomide chemotherapy [22]. In order to
test if there was any relationship between RECQ1
expression and MGMT status, we investigated the
methylation status of the MGMT gene promoter region
Figure 3 RECQ1 expression in human brain glioblastomas.A )
Western blot analyses of surgically removed perilesional (lanes
2,4,6,8) and lesional tissues from glioblastoma multiforme (lanes
1,3,5,7) performed using the anti-RECQ1 RQ-FL antibody. Alpha-
tubulin protein was used as an internal control to guarantee that
the amount of proteins loaded on each well was the same. B)
Representative immunostaining of RECQ1 expression in normal
autoptic brain tissues (top), and perilesional and lesional
glioblastoma tissues (bottom) performed using the anti-RECQ1 RQ-
FL antibody and the Benchmark automatic immunostaining device
(Ventana Medical System, Tucson, AZ, USA). Immunostaining was
made using the anti-RECQ1 RQ-FL antibody. The nuclei positive for
RECQ1 are in brown and the tissues were counterstained with
hematoxylin (normal autoptic brain tissues, O.M 40X; perilesional
and lesional glioblastoma tissues, O.M. 40X). B) Immunostaining for
RECQ1 on human normal heart tissue counterstained with
hematoxylin (O.M 20X).
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mas characterized by a staining nuclear intensity value
in IHC of 3+. Statistical analysis on this set of data
clearly showed that there was no correlation between
the percentage of RECQ1 positive cells and the methyla-
tion status of the MGMT promoter region in primary
glioblastoma tissues (P = 0.3757). Similar results in
terms of no statistical significance were obtained when
considering the status of MGMT protein expression in
the same subgroup of glioblastomas (P = 0.2309) (Addi-
tional File 2). Recent mutational analyses also revealed
that somatic mutations in the NADP-dependent isoci-
trate dehydrogenase genes, IDH1 and IDH2,w e r ea s s o -
ciated with an increased overall survival of glioblastoma
patients [27,32,33]. However, these mutations are rare in
primary glioblastomas (grade IV)–the group of gliomas
Figure 4 RECQ1 expression in TMA from human brain glioblastomas. A) Representative immunostaining of RECQ1 expression in tissue core
derived from a glioblastoma specimen and B) corresponding normal surrounding tissue (magnification 40×). C) Box plot representing the count
of cell positive for RECQ1 in 19 brain glioblastomas and paired peri-lesional tissues independently of the staining intensity of the samples. D) Pie
chart presenting the distribution of the staining intensity for RECQ1 in 63 brain glioblastomas and 19 paired peri-lesional tissues E) Box plot
representing the count of cell positive for Ki-67 in 19 brain glioblastomas and paired peri-lesional tissues. The boxes summarize the confidence
interval (lower and higher horizontal lines), 25
th-50
th and 75
th percentiles (horizontal lines of the box).
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Page 8 of 17used in this work– while are most frequent in tumors
that evolved from lower-grade gliomas (secondary glio-
blastomas) [27,33]. In agreement with these findings,
our preliminary analysis of the IDH genes showed that
both IDH1 and IDH2 genes were wild type in our group
of primary glioblastoma tissues (data not shown). In
summary, our TMA analysis confirmed that the expres-
sion of RECQ1 is significantly increased in the glioblas-
toma tissues relative to perilesional tissues. Moreover,
RECQ1 protein overexpression does not seem to have a
prognostic value associated with MGMT methylation
status in primary glioblastoma multiforme.
RECQ1 silencing inhibits cell proliferation in glioblastoma
cells
To test the role of RECQ1 in glioblastoma cell growth
and proliferation, we compared the colony forming
properties of two different glioblastoma cell lines (T98G
and U-87), and normal human IMR-90 fibroblasts, tran-
siently transfected with RECQ1-specific siRNAs versus
cells transfected with a luciferase siRNA duplex, as con-
trol (Figure 5). More than 80% depletion of RECQ1 was
observed in all whole cell extracts upon treatment with
the RECQ1-specific siRNA duplex as compared to the
control cells (Figure 5A). Our colony forming assays
demonstrated a significant reduction in both the size
and number of colonies of RECQ1 downregulated T98G
and U-87 glioblastoma cells (Figure 5B,C). However, the
downregulation of RECQ1 in normal human primary
fibroblasts did not significant l ya f f e c tt h ep r o l i f e r a t i o n
capacity of these cells in agreement with previous find-
ings [19].
The same experiments were then repeated on a T98G
cell line stably transfected with a plasmid codifying a
RECQ1-specific shRNA (Figure 6). A comparison of
selected G418 resistant clones that carry the plasmid
codifying the RECQ1 shRNA with control cells contain-
ing the empty vector enabled us to assess the effect of
stable RECQ1 depletion on the colony forming ability of
RECQ1-depleted T98G cells. In agreement with the
results obtained with the siRNA mix, our colony form-
ing assays showed a significant reduction in both size
and number of colonies when T98G cells were stably
downregulated for RECQ1. In particular, RECQ1-
depleted glioblastoma cells showed ~10 fold reduction
in their proliferative capacity in comparison with control
cells (from 5.3% to 59.4%). Collectively, our data point
t oas p e c i f i cr e g u l a t o r yr o l eo fh u m a nR E C Q 1i nt h e
proliferation in glioblastoma cells.
RECQ1 depletion leads to cell cycle perturbation in T98G
glioblastoma cells
Previous studies showed that siRNA-mediated deple-
tion of RECQ1 impairs cellular proliferation in
different cell lines [19]. This notion was also supported
by our FACS analysis of RECQ1-depleted T98G glio-
blastoma cells that had been bromodeoxyuridine
(BrdU)-labelled, indicating that there is more than 50%
reduction in both BrdU labelling and S phase fraction.
This reduction of S phase cells is associated to an
increased fraction of cells arrested in G1 (Figure 7A
and 7B). These results confirm that RECQ1 depletion
suppresses cell proliferation, and may do so by inter-
fering with DNA synthesis.
In order to provide additional data on the role of
RECQ1 in DNA synthesis and cell proliferation, we
Figure 5 Proliferative capacity of RECQ1-depleted glioblastoma
cells. A) Western blot analysis of T98G, U-87 and IMR-90 cell lines
transiently transfected with an siRNA against RECQ1. L indicates the
Luciferase siRNA control, R the siRNA against RECQ1. B) Clonogenic
assays performed in RECQ1-depleted T98G, U-87, and IMR-90 cell
lines. Pictures show colonies formed after seeding 800 cells. C)
Graphs showing the plating efficiencies expressed as colony
forming capacity. Values represent the average ratio of the number
of formed colonies to the number of cells seeded, expressed as
percentage.
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depleted cells upon replication stress induction with
hydroxyurea. Cellular survival curves at increasing
hydroxyurea concentrations showed that RECQ1
depleted cells were hyper-sensitive to hydroxyurea treat-
ment suggesting a possible role of RECQ1 in DNA
replication fork processing (Figure 7C).
RECQ1 depletion in glioblastoma cells results in an
increased load of DNA damages
RecQ helicases are involved in the stabilization and
repair of damaged DNA replication forks in response
to endogenous or exogenous stress [34]. A failure to
stabilize forks can lead to fork collapse and DNA
breaks [35]. Consistently, previous studies with RECQ1
deficient HeLa cells showed an increased level of DNA
damage and sister chromatid exchanges upon RECQ1
depletion [36]. To confirm that RECQ1 has the same
role in glioblastoma cells, we analyzed the extent of
spontaneous g-H2AX foci formation in control or
RECQ1 siRNA transfected T98G and U-87 cells (Fig-
ure 8). The phosphorylated form of histone H2AX (g-
H2AX) is a well-known marker of DNA breaks in cells
[37]. Our immunoblots using an antibody against g-
H2AX confirmed previous observations of an increased
load of DNA lesions upon RECQ1 depletion (Figure
8A). Consistently, our immunofluorescence experi-
ments indicated that RECQ1 depletion results in a dra-
matic increase in spontaneous g-H2AX foci formation
confirming that the reduced expression of RECQ1 is
associated with defects in DNA repair (Figure 8B,C).
Approximately 50% of the RECQ1 depleted cells con-
tained more than ten g-H2AX foci per nucleus, com-
p a r e dt oo n l y1 5 %o ft h ew i l d - t y p ec e l l s .P r e v i o u s
studies suggested that RecQ helicases play an impor-
tant role in homologous recombination (HR) repair at
sites of chromosomal DNA damage [3]. To test if
R E C Q 1i sa l s oi n v o l v e di nt h i sp a t h w a y ,w ea n a l y z e d
t h ea b i l i t yo fR A D 5 1 ,ap r o t e i ni n v o l v e di nt h es t r a n d
invasion step of HR repair, to form foci in RECQ1
depleted T98G cells. As shown in Figure 9, the RECQ1
depleted cells exhibited an increased number of spon-
taneous RAD51 foci relative to the control cells. How-
ever, the increase in the number of RAD51 foci is less
pronounced compared with the g-H2AX foci suggest-
ing the double-strand breaks might not be the major
form of damage that leads to g-H2AX foci formation
in the absence of RECQ1.
Figure 6 Proliferative capacity of T98G cells stably transfected with a shRNA against RECQ1. A) Clonogenic assay performed in either
control cells (left plate) and in clones silenced for RECQ1 (right plate). The figure shows colonies formed after plating 100, 200, 400, 800, 1600
and 3200 cells (well 1 to well 6, respectively). B) Graph showing the plating efficiencies expressed as colony forming capacity. Values represent
the average ratio of the number of formed colonies to the number of cells seeded, expressed as percentage.
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Page 10 of 17Figure 7 Downregualtion of RECQ1 leads to defects in cell cycle progression and DNA synthesis in glioblastoma T98G cells. A) Flow
cytometry profiles of DNA content (x-axis; propidium iodide/PI staining) versus BrdU incorporation (y-axis; anti-BrdU immunostaining) 72 h after
siRNA transfection. Boxes are labeled to indicate cell cycle phases. B) The bar graph at bottom reports the percentage of G0/G1, S-phase/BrdU
positive and G2/M cells in cultures that had been transfected with RECQ1 or luciferase/control siRNA pools. Results shown are the mean ± SEM
from three independent experiments. C) The graph shows the cellular surviving fractions measured at different doses of hydroxyurea in control
and RECQ1-depleted T98G cells. Surviving fraction values are the mean ± SEM from three independent experiments.
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temozolomide treatment
To explore the possibility that RECQ1 might represent
a suitable new target for brain tumor treatment, we
investigated the sensitivity of glioblastoma cells to
temozolomide (TMZ), which is a commonly used
anticancer agent for the treatment of human brain
tumors [21-23]. TMZ is an alkylating agent that effec-
tively inhibits glioblastoma cell proliferation. Its toxi-
city is primarily due to formation of O6-methylguanine
Figure 8 Downregulation of RECQ1 triggers spontaneous g-H2AX foci accumulation. A) Western blot analysis of T98G cell lines transiently
transfected with an siRNA against RECQ1. L indicates the Luciferase siRNA control, R the siRNA against RECQ1. B) Immunostaining of
endogenous RECQ1 and endogenous g-H2AX on T98G cells after treatment with anti-RECQ1 siRNA or control siRNAs. C) The graph shows the
percentage of cells that contain a defined number of g-H2AX foci per cell.
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replication cycles and after accumulation of unrepaired
DNA mismatches results in cell death [38,39]. Thus,
we analysed the colony forming capacity of RECQ1-
depleted glioblastoma cell lines after treatment with
TMZ (Figure 10). Cellular survival curves using
increasing TMZ concentrations showed that RECQ1
depleted T98G and U87 cell lines were hypersensitive
to the action of TMZ suggesting a possible role of
RECQ1 in DNA repair pathways linked to DNA
Figure 9 Downregualtion of RECQ1 triggers spontaneous RAD51 foci accumulation. A) Western blot analysis of T98G cell lines transiently
transfected with a RECQ1-specific siRNA duplex. L indicates the Luciferase siRNA control, R the siRNA against RECQ1. B) The pictures show the
immunostaining of endogenous RECQ1 and RAD51 on T98G cells after treatment with anti-RECQ1 siRNA or control siRNAs. C) The graph shows
the percentage of cells that contain a defined number of RAD51 foci per cell.
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represent a suitable new target for the inhibition of
cell proliferation in brain tumors.
Given that the status of MGMT and IDH genes are
central in the treatment and/or prognosis of glioblas-
toma tumors [32], we investigated the methylation sta-
tus of the MGMT gene and the presence of
stereotypical mutations of IDH genes in the T98G, U-87
and IMR90 cell lines that were used in the RNA inter-
ference experiments (Additional File 3). Our results
showed that the T98G and U-87 glioblastoma cell lines
were both methylated at the MGMT gene promoter,
while the primary human fibroblasts IMR-90 had unmo-
dified MGMT alleles (Additional File 3A). These results
indicate that the T98G and U-87 cells are likely to be
more susceptible to the cytotoxic effect of temozolomide
treatment compared to cells carrying unmodified
MGMT. On the other hand, sequence analysis showed
that the residues R132 and R172 of the IDH1 and IDH2
genes, respectively, were no mutated in all cell lines ana-
lyzed (Additional File 3B). Moreover, the MGMT pro-
moter methylation status and stereotypical mutated
codons in IDH genes did not change upon RECQ1
silencing after RNA interference indicating that the
changes in TMZ sensitivity observed upon RECQ1
downregulation are not associated with modifications in
the MGMT and IDH genes.
Discussion
In this work, we used immunohistochemical and wes-
tern analysis to show that RECQ1 is highly expressed in
human brain glioblastoma and it is confined in the
nuclei of the tumor cells, suggesting that this protein
plays an important role in glioblastoma tumor growth.
This conclusion was validated on a tissue microarray
containing a total of primary 63 glioblastoma and 19
perilesional tissues and indicated that the higher expres-
sion of RECQ1 in the tumors is not related to the sex
or the age of the individuals. RECQ1 expression is also
not related to the methylation status of the MGMT
gene which identifies a subgroup of glioblastoma more
susceptible to the cytotoxic effect of temozolomide
treatment. Interestingly, we see that RECQ1 is also
highly expressed in other types of tumors, in agreement
with previous findings [40,41]. However, only in the
case of brain tumors, the high expression of RECQ1 is
paralleled to a reduced expression of the same protein
in perilesional and/or normal tissues, possibly due to the
low degree of proliferation of brain cells. Hence, we
believe that RECQ1 would be an ideal target for che-
motherapy especially in the case of brain tumors since
its depletion by RNAi, or its inhibition by selective com-
pounds, would primarily affect tumoral cells.
An essential role of RECQ1 in tumor growth and pro-
liferation is confirmed by our clonogenic assays where
we noticed a significant reduction in the number of
colonies when T98G and U87 cells were inhibited for
the expression of RECQ1. This notion is supported by
our previous observation that RECQ1 plays an impor-
tant role during DNA replication, which is distinct from
that of other human RecQ helicases [29]. In addition,
we previously showed that RECQ1, BLM, and WRN are
characterized by different substrate specificities [42]. In
agreement with these findings, Sharma et al. showed
that RECQ1 is important for HeLa cell proliferation and
plays a unique role in the maintenance of genome integ-
rity [36,43]. Consistently, we find that the depletion of
RECQ1 results in spontaneous g-H2AX foci formation
and HU hypersensitivity in T98G cells, suggesting that
RECQ1 plays an important and unique role in DNA
repair during DNA replication. Concerning the specific
role of RECQ1 in genome maintenance, Sharma et al.
Figure 10 RECQ1 downregulated glioblastoma cells are
hypersensitive to TMZ treatment. The graphs show the cellular
surviving fractions measured at different doses of temozolomide in
control and RECQ1-depleted T98G and U-87 cells. Surviving fraction
values are the mean ± SEM from three independent experiments.
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tion of the homologous recombination pathway of DNA
double-strand break repair [36]. Interestingly, our
immunofluorescence experiments indicate that RECQ1
loss results in fewer RAD51 foci compared to g-H2AX
foci indicating that RECQ1 might not play a major role
in homologous recombination (HR). Consistently, we do
not observe any significant defect in HR frequency in
RECQ1 siRNA-inhibited cells (indeed, HR frequency
was slightly increased upon RECQ1 depletion) (data not
shown). The hyper-recombination phenotype of
RECQ1-depleted cells suggests either that RECQ1 is
involved in the suppression of some illegitimate recom-
bination events, as already proposed for other helicases
of the same family [44], or that loss of RECQ1 results in
the accumulation of some form of DNA lesion or strand
breaks, other than DSBs, that might subsequently lead
to repair by HR if not properly repaired.
The resistance of glioma cells to TMZ is mainly asso-
ciated with levels of the DNA repair protein O
6-alkyl-
guanine alkyltransferase (AGT), which removes alkyl
groups at the O
6 position of guanine. In fact, O6-benzyl-
guanine (O6-BG), an inhibitor for AGT, reduces resis-
tance to TMZ [45]. Moreover, it has been demonstrated
that chemosensitivity of tumor cells to TMZ correlates
with the inhibition of telomerase activity [46]. Our stu-
dies using malignant glioma cell lines with low (U87-
MG) and high levels of AGT (T98G), show that RECQ1
suppression by RNA interference increases the sensitiv-
ity of these cells to TMZ, independently of the AGT
expression levels. Our data show also that the hypersen-
sitivity of the RECQ1 depleted cells to TMZ is not
linked to the methylation status of the MGMT gene
which is methylated in both T98G and U87 cells or to
the presence of stereotypical mutations in the IDH1 and
IDH2 genes which are absent in these cells. The
increased sensitivity of RECQ1 depleted glioblastoma
cells to TMZ support the notion that RECQ1 plays a
unique role in DNA repair during DNA replication in
malignant cells.
Interestingly, a recent study showed that RECQ1 silen-
cing in cancer cells induces a cell specific mitotic cata-
strophe not observed in normal cells [19]. The absence
of RECQ1 might promote the accumulation of DNA
damage in the M-phase arrested cells due to the defi-
cient G1 and G2 checkpoint functions of cancer cells.
These events would then lead to this cell type specific
mitotic death. Under normal conditions, the accumula-
tion of DNA damage and mitotic cell death is avoided
during the S and G2 phases by the upregulation of dif-
ferent repair enzymes, such as RECQ1. Thus, cancer
cells might maintain a greater copy number of DNA
repair enzymes to restore DNA damage in a short time
since the normal time of cell cycle arrest needed for
DNA repair during the S and G2 phases is unavailable
due to defects in the checkpoint activity.
Defects in the genes of three of the five human DNA
helicases, BLM, WRN and RECQ4, are responsible for
distinct genetic disorders associated with cancer predis-
position. Moreover, allelic losses or deletion of chromo-
some 12p12, where the RECQ1 gene is located, is a
frequent event in a wide range of solid tumors [47-50],
and a single-nucleotide polymorphism of the RECQ1
gene has been associated with a reduced survival of pan-
creatic cancer patients [9,10]. In this regard, RecQ heli-
cases might be considered as “tumor suppressors” that
prevent neoplastic transformation through the control
of chromosomal stability. The fact that RecQ helicases,
such as BLM and RECQ1, are upregulated in tumors
and provide growth advantage to cancer cells might
appear incompatible with the proposed tumor suppres-
sion function of these proteins. Recent studies indicated
that WRN also supports oncogenic proliferation [17].
Indeed, the expression of several RecQ helicases is also
increased upon cellular transformation by EBV and
SV40 antigen [41]. A possible explanation for this para-
dox is that, in somatic cells, DNA repair defects affect-
ing genome integrity due to a RecQ helicase deficiency
may lead to cancer predisposition. Conversely, increased
RecQ helicase expression might be required in trans-
formed or actively proliferating cells to resolve and
repair the elevated load of DNA intermediates that are
generated during active replication.
Conclusions
Taken together, our results indicate that RECQ1 might
be considered as a new suitable target for the develop-
ment of anti-cancer therapies aimed at the elimination of
proliferating tumor cells. In this regard, previous studies
provided evidence that local and systemic administration
of RECQ1-siRNA prevented cancer cell proliferation in
vivo in mouse models [18,20]. These studies neglected
however human brain glioblastomas, which are, in our
opinion, the best type of human tumor where a similar
strategy could be applied, given the low amount of
RECQ1 present in normal brain cells. Similarly, other
DNA repair helicases have been previously proposed as
potential targets for anti-tumor therapies mediated by
DNA damaging agents or radiation, opening the possibi-
lity of using small-molecule inhibitors against DNA heli-
cases as novel chemiotherapeutic agents [51,52].
Additional material
Additional file 1: Representative image of the GFAP staining in a
peri-lesional (A) and lesional (B) glioma tissue. The arrows indicate
the astrocytes (A), which are positive to the antibody, the
oligodentrocytes (O) and the support neurons (N).
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Page 15 of 17Additional file 2: MGMT status in primary glioblastoma highly
expressing RECQ1. A) Box plot representing the count of RECQ1
positive cells expressing in percentage and the methylation status of the
MGMT gene from 41 brain primary glioblastomas with staining intensity
of 3+ for RECQ1. B) Box plot representing the count of RECQ1 positive
cells and MGMT protein expression from 41 brain primary glioblastomas
with staining intensity of 3+ for RECQ1.
Additional file 3: MGMT and IDH status in T98G and U-87
glioblastoma cell lines. A) Gel showing the specific DNA amplicons for
unmethylated (uM) and methylated (M) genomic sequences at the 5’ of
the MGMT gene. MGMT methylation status upon RECQ1 downregulation
in different cell lines was also performed using the methylation specific
PCR analysis. (MW: DNA marker) B) Representative sequencing
chromatograms on IDH1 and IDH2 genes in T98G, U-87 and IMR-90 cells.
Dashed boxes indicate the residues R132 and R172 of the IDH1 and IDH2
genes, respectively.
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